SELLAS Life Sciences Group, Inc. (SLS)Healthcare | Biotechnology | New York, United States | NasdaqCM
4.99 USD
Short-term: ★★★☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:51 a.m. EDT
High-beta clinical trial play with massive options speculation on a future catalyst but immediate downside risk heavily hedged. The company is cash-rich with minimal debt, making a downside wave financially unlikely unless operational failures occur, but the -28.99 forward PE and negative earnings create a binary outcome signal: a trial readout drives a 5-10x tradable move, while a miss triggers years to recover. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.129981 |
| AutoTheta | 0.398234 |
| AutoARIMA | 0.457078 |
| MSTL | 0.479307 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 71% |
| H-stat | 1.28 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.315 |
| Excess Kurtosis | -1.11 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.412 |
| Market Cap | 896,116,992 |
| Forward P/E | -27.72 |
| Beta | 2.23 |
| Website | https://sellaslifesciences.com |
As of April 19, 2026, 12:51 a.m. EDT: Options positioning shows high-degree of ambiguity. Call flow is significant but highly OTM and clustered at future expirations (May/June), suggesting speculative positions for a potential clinical trial breakthrough rather than immediate gains, evidenced by high volume (>500) at strikes 6.0, 7.0, and 8.0. However, put options on the April 17th expiration show massive hedge positioning (over 5,000 volume) against the ATM 5.0 strike. This creates a 'war of attrition' where speculators buy deep OTM calls while risk management hedges with ATM/O TM puts, indicating no clear consensus on direction for the next week.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.868217 |
| Address1 | 7 Times Square |
| Address2 | Suite 2503 |
| All Time High | 718,500.0 |
| All Time Low | 0.5 |
| Ask | 5.23 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 4,275,610 |
| Average Daily Volume3 Month | 6,391,714 |
| Average Volume | 6,391,714 |
| Average Volume10Days | 4,275,610 |
| Beta | 2.232 |
| Bid | 4.98 |
| Bid Size | 3 |
| Board Risk | 3 |
| Book Value | 0.463 |
| City | New York |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.99 |
| Current Ratio | 10.718 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.075 |
| Day Low | 4.86 |
| Debt To Equity | 1.412 |
| Display Name | SELLAS Life Sciences |
| Dividend Date | 1,573,171,200 |
| Earnings Timestamp | 1,773,950,400 |
| Earnings Timestamp End | 1,778,616,000 |
| Earnings Timestamp Start | 1,778,616,000 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 825,325,056 |
| Eps Current Year | -0.28333 |
| Eps Forward | -0.18 |
| Eps Trailing Twelve Months | -0.25 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.7226 |
| Fifty Day Average Change | 0.2673998 |
| Fifty Day Average Change Percent | 0.05662131 |
| Fifty Two Week Change Percent | 286.8217 |
| Fifty Two Week High | 6.14 |
| Fifty Two Week High Change | -1.1500001 |
| Fifty Two Week High Change Percent | -0.18729644 |
| Fifty Two Week Low | 1.26 |
| Fifty Two Week Low Change | 3.7299998 |
| Fifty Two Week Low Change Percent | 2.9603174 |
| Fifty Two Week Range | 1.26 - 6.14 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,205,328,600,000 |
| Float Shares | 178,817,552 |
| Forward Eps | -0.18 |
| Forward P E | -27.72222 |
| Free Cashflow | -18,497,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 13 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0061299996 |
| Held Percent Institutions | 0.20305 |
| Implied Shares Outstanding | 179,582,574 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,573,171,200 |
| Last Split Factor | 1:50 |
| Long Business Summary | SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. |
| Long Name | SELLAS Life Sciences Group, Inc. |
| Market | us_market |
| Market Cap | 896,116,992 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_262231850 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -26,863,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 897,014,957 |
| Number Of Analyst Opinions | 3 |
| Open | 5.04 |
| Operating Cashflow | -28,389,000 |
| Operating Margins | 0.0 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 646 200 5278 |
| Previous Close | 4.99 |
| Price Eps Current Year | -17.61197 |
| Price Hint | 4 |
| Price To Book | 10.777537 |
| Profit Margins | 0.0 |
| Quick Ratio | 10.231 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 5.075 |
| Regular Market Day Low | 4.86 |
| Regular Market Day Range | 4.86 - 5.075 |
| Regular Market Open | 5.04 |
| Regular Market Previous Close | 4.99 |
| Regular Market Price | 4.99 |
| Regular Market Time | 1,776,790,465 |
| Regular Market Volume | 2,661,973 |
| Return On Assets | -0.3474 |
| Return On Equity | -0.66877 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 179,582,574 |
| Shares Percent Shares Out | 0.2981 |
| Shares Short | 53,525,042 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 49,129,452 |
| Short Name | SELLAS Life Sciences Group, Inc |
| Short Percent Of Float | 0.2998 |
| Short Ratio | 6.47 |
| Source Interval | 15 |
| State | NY |
| Symbol | SLS |
| Target High Price | 10.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 8.66667 |
| Target Median Price | 10.0 |
| Total Cash | 71,793,000 |
| Total Cash Per Share | 0.4 |
| Total Debt | 1,001,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.25 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.844 |
| Two Hundred Day Average Change | 2.1459997 |
| Two Hundred Day Average Change Percent | 0.7545709 |
| Type Disp | Equity |
| Volume | 2,661,973 |
| Website | https://sellaslifesciences.com |
| Zip | 10,036 |